Doxurra 0,5 mg Tablets
PDF Leaflet Revision Date: 15 April 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Inhibition of lactation and treatment of hyperprolactinemic disorders.
Dosage (summary)
1 mg as a single dose for lactation inhibition; 0.5 mg weekly for hyperprolactinemia, adjusted as needed.
Onset of Action / Duration
Onset: 3 hours, Duration: up to 28 days
Special Populations
- Elderly
- Hepatic impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Dopamine antagonists
- Macrolide antibiotics
- Other medicines lowering blood pressure
Contraindications
- Hypersensitivity to cabergoline
- Pregnancy
- Breastfeeding
- Hepatic insufficiency
Common side effects
- Dizziness
- Nausea
- Hypotension
- Somnolence
Counselling Points
- Monitor for hypotension
- Avoid driving if affected
- Use contraception during treatment
Serious warnings
- Risk of fibrotic disorders
- Impulse control disorders
- Somnolence
Important Disclaimer
The Doxurra 0,5 mg Tablets professional information leaflet below is the property of Pharmacare Limited and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
